Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Last updated: September 14, 2023
Sponsor: Far Eastern Memorial Hospital
Overall Status: Active - Recruiting

Phase

3

Condition

Interstitial Cystitis

Treatment

Mirabegron

Solifenacin

Clinical Study ID

NCT04023253
108003-F
  • Ages > 20
  • Female

Study Summary

To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Overactive bladder syndrome

Exclusion

Exclusion Criteria:

  • Allergy to mirabegron or solifenacin.
  • Patients with severe hypertension who are difficult to control, known urethraldiverticulum, known bladder malignant tumors, urinary retention patients, gastricretention patients, uncontrolled angular glaucoma patients, dialysis patients, severerenal dysfunction , moderate liver dysfunction, use strong inhibitors of CYP3A4 suchas ketoconazole.

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Mirabegron
Phase: 3
Study Start date:
August 01, 2019
Estimated Completion Date:
December 31, 2024

Study Description

To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and blood flow.

Connect with a study center

  • Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

    Banqiao, New Taipei 22050
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.